CSIMarket
 
T2 Biosystems Inc   (TTOO)
 

Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season

TTOO recorded third quarter of 2022 operating deficit of $-15.8 million


Published Mar 22 2023
CSIMarket Team / CSIMarket.com


tomography_pd the Medical Equipment & Supplies company reported disastrous financial period ending September 30 2022, where Revenue faded by -50.498 % to $3.68 million and net loss per share has extended to $-2.95, from the corresponding reporting period a year before.

from the preceding reporting period from $-0.10 per share, Revenue Tumbled from the by -37.794 % from $5.91 million.


For the third quarter of 2022 T2 Biosystems Inc realized net loss of $-17.375 million, higher than $-13.962 million a year ago.


T2 Biosystems Inc is expected to report next financial earnings on May 11, 2023.



T2 Biosystems Inc's Dividend Growth

T2 Biosystems Inc's Receivables Turnover Ratio



Other TTOO's news

T2 Biosystems Extends Capital Equipment Supplier Agreement with Vizient, Inc., Strengthening Detection of Sepsis-Causing Pathogens and Antibiotic Resistance Genes

T2 Biosystems Unveils T2Lyme Launch Plans and Projections for Future Success

T2 Biosystems Strengthens Disease Diagnostics with T2Lyme Launch and Expanded Bacteria Panel

Advancements in T2Resistance Panel Enable Faster Targeted Therapy for Drug-Resistant Infections

T2 Biosystems: Building a Stronger Future Through Strategic Financial Moves

T2 Biosystems Accelerates Global Expansion with Exclusive Distribution Partnerships in Europe and Asia, Strengthening the Fight Against Sepsis

T2 Biosystems Introduces Enhanced T2Bacteria Panel, Expanding Bacterial Detection Capability to Combat Healthcare-associated Infections

T2 Biosystems Joins Forces with NIH in Groundbreaking Study to Revolutionize Pneumonia Diagnosis

T2 Biosystems Inc. Announces Split-Adjusted Basis for Common Stock Trading in Efforts to Benefit Shareholders

T2 Biosystems Announces Inducement Awards for New Employees, Reflecting Company*s Commitment to Combating Sepsis

T2 Biosystems Struggles Amidst Stock Decline and Financial Losses

T2 Biosystems Inc Brings Innovation Amidst Declining Revenue, Achieves Milestone With Decreased Losses Per Share

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season



Other TTOO's news

T2 Biosystems Extends Capital Equipment Supplier Agreement with Vizient, Inc., Strengthening Detection of Sepsis-Causing Pathogens and Antibiotic Resistance Genes

T2 Biosystems Unveils T2Lyme Launch Plans and Projections for Future Success

T2 Biosystems Strengthens Disease Diagnostics with T2Lyme Launch and Expanded Bacteria Panel

Advancements in T2Resistance Panel Enable Faster Targeted Therapy for Drug-Resistant Infections

T2 Biosystems: Building a Stronger Future Through Strategic Financial Moves

T2 Biosystems Accelerates Global Expansion with Exclusive Distribution Partnerships in Europe and Asia, Strengthening the Fight Against Sepsis

T2 Biosystems Introduces Enhanced T2Bacteria Panel, Expanding Bacterial Detection Capability to Combat Healthcare-associated Infections

T2 Biosystems Joins Forces with NIH in Groundbreaking Study to Revolutionize Pneumonia Diagnosis

T2 Biosystems Inc. Announces Split-Adjusted Basis for Common Stock Trading in Efforts to Benefit Shareholders

T2 Biosystems Announces Inducement Awards for New Employees, Reflecting Company*s Commitment to Combating Sepsis

T2 Biosystems Struggles Amidst Stock Decline and Financial Losses

T2 Biosystems Inc Brings Innovation Amidst Declining Revenue, Achieves Milestone With Decreased Losses Per Share

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

Very steep Deterioration at TTOO amid the third quarter of 2022 earnings season



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com